Translating Preclinical Toxicology & Efficacy Insights into a Successful IND

• Evaluate in vitro discovery and investigative toxicology in cell therapy platforms to define target biology, evaluate therapeutic liabilities, and establish early human relevance
• Review fit-for-purpose in vivo models in cell therapies to integrate safety with efficacy, PK, and biodistribution, while acknowledging species differences and model limitations
• Discover a strategy integrating in vitro and in vivo data to address safety liabilities while leveraging efficacy strengths for a regulatory-aligned IND in cell therapy

Speakers:

Raghu Tadagavadi

Executive Director, Head of Nonclinical Development & Toxicology

Century Therapeutics